JANX · Janux Therapeutics, Inc. · Executive Compensation

$17.20 +0.46 (+2.75%)

Russell 2000 member Rebalance outlook locked

Market Cap

$1.02B

61.14M

Volume · Oct 20 862.06K Avg daily vol (3M) 844.94K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Campbell	President and Chief Executive Officer	$680,000	—	—	$12,459,031	$367,200	—	$13,506,231
Byron Robinson	Ph.D., J.D. Former Chief Strategy Officer	$362,728	—	—	$4,306,826	—	$394,081	$5,063,635
Janeen Doyle	Chief Corporate and Business Development Officer	$309,963	$75,000	$995,280	$3,124,983	$114,066	$50,000	$4,669,292
Zachariah McIver	D.O., Ph.D. Former Chief Medical Officer	$475,000	—	—	$3,999,195	$165,300	—	$4,639,495
Thomas DiRaimondo	Chief Scientific Officer	$478,000	—	—	$3,691,565	$175,904	—	$4,345,469

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Campbell	President and Chief Executive Officer	$646,000	—	$4,981,500	$2,862,873	$484,500	—	$8,974,873
Tighe Reardon	Former Acting Chief Financial Officer	—	—	—	$7,913,496	—	—	$7,913,496
Byron Robinson	Ph.D., J.D. Chief Strategy Officer	$485,000	—	$1,871,520	$1,216,621	$242,500	—	$3,815,641
Thomas DiRaimondo	Chief Scientific Officer	$420,000	—	$1,604,160	$1,180,484	$210,000	—	$3,414,644

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Campbell	President and Chief Executive Officer	$625,000	—	—	$3,155,769	$412,500	—	$4,193,269
Byron Robinson	Ph.D., J.D. Chief Strategy Officer	$450,000	$75,000	—	$1,017,990	$198,000	—	$1,740,990
Charles Winter	Chief Technical Officer	$410,000	—	—	$1,017,990	$180,400	—	$1,608,390

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Campbell	President and Chief Executive Officer	$550,000	—	—	$5,149,378	$302,500	—	$6,001,878
Byron Robinson	Ph.D., J.D. Chief Strategic Officer	$351,945	$100,000	—	$2,760,989	$154,856	—	$3,367,790
Wayne Godfrey	Chief Medical Officer	$435,000	—	—	$1,660,738	$191,400	—	$2,287,138
Charles Winter	Chief Technical Officer	$315,000	—	—	$1,133,808	$103,950	—	$1,552,758

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Campbell	President and Chief Executive Officer	$459,054	—	—	$7,721,848	$229,527	—	$8,410,429
Wayne Godfrey	Chief Medical Officer	$257,045	—	—	$3,918,086	$102,818	—	$4,277,949
Shahram Salek-Ardakani	Chief Scientific Officer	$189,394	$125,000	—	$3,638,223	$56,818	—	$4,009,435
Byron Robinson	Ph.D., J.D. Chief Strategy Officer	—	—	—	—	—	—	—

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
David Campbell	President and Chief Executive Officer	$405,117	$141,791	—	$225,868	—	$38,906	$811,682
Wayne Godfrey	Chief Medical Officer	—	—	—	—	—	—	—
Shahram Salek-Ardakani	Chief Scientific Officer	—	—	—	—	—	—	—

Executive changes

Person	Role	Change	Effective	Filed
Eric Dobmeier	Class II director	Appointed	2026-04-28	2026-04-28
Eric Dobmeier	Class III director	Resigned	2026-04-28	2026-04-28
Byron Robinson, Ph.D.	Chief Strategy Officer	Terminated	2025-09-18	2025-09-19
Eric Dobmeier	Class III director of the Company	Appointed	2024-07-19	2024-07-22
Ron Barrett, Ph.D.	Chair of the Board	Appointed	2024-07-19	2024-07-22
Natasha Hernday	Class II director of the Company	Appointed	2024-07-19	2024-07-22
Jay Lichter, Ph.D.	member of the Board of Directors (the "Board") of Janux Therapeutics, Inc. (the "Company"), including his chairmanship of the Bo	Resigned	2024-07-19	2024-07-22
Wayne Godfrey, M.D.	Chief Medical Officer	Resigned	2023-07-05	2023-06-23
Stefan Heller, Ph.D.	member of the Board	Resigned	2022-09-21	2022-09-22
Winston Kung	Class I director	Appointed	2022-09-21	2022-09-22

Leadership

David Campbell CEO, Board Member
Ron Barrett, Ph.D. Chairman
Tighe Reardon CFO
Alana McNulty Board Member
Eric Dobmeier Board Member
Natasha Hernday Board Member
Ronald Barrett, Ph.D. Board Member
Winston Kung Board Member

Key facts CIK 1817713 CUSIP 47103J105 13F (30d) 14 filings 14 filers Visit website Investor relations